These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30574167)

  • 21. Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment.
    Berger W; Meltzer EO; Amar N; Fox AT; Just J; Muraro A; Nieto A; Valovirta E; Wickman M; Bousquet J
    Pediatr Allergy Immunol; 2016 Mar; 27(2):126-33. PubMed ID: 26928753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-Life Effectiveness of MP-AzeFlu (Dymista
    Stjärne P; Nguyen DT; Kuhl HC
    Pragmat Obs Res; 2023; 14():1-11. PubMed ID: 36628265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival.
    Mullol J; Roca-Ferrer J; Alobid I; Pujols L; Valero A; Xaubet A; Bernal-Sprekelsen M; Picado C
    Clin Exp Allergy; 2006 Jan; 36(1):52-8. PubMed ID: 16393266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
    Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C
    Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
    Kortekaas Krohn I; Callebaut I; Alpizar YA; Steelant B; Van Gerven L; Skov PS; Kasran A; Talavera K; Wouters MM; Ceuppens JL; Seys SF; Hellings PW
    Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy.
    Watts AM; West NP; Smith PK; Zhang P; Cripps AW; Cox AJ
    Immun Inflamm Dis; 2022 Mar; 10(3):e571. PubMed ID: 34813682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis.
    Zhong Z; Xun Y; Shi X; Guan B; Wang M
    Eur Arch Otorhinolaryngol; 2022 May; 279(5):2457-2464. PubMed ID: 34415405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu
    Marth K; Renner A; Langmayr G; Pohl W; Nguyen DT; Kuhl HC
    Drugs Real World Outcomes; 2024 Jun; 11(2):231-240. PubMed ID: 38351402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival.
    Mullol J; Callejas FB; Méndez-Arancibia E; Fuentes M; Alobid I; Martínez-Antón A; Valero A; Picado C; Roca-Ferrer J
    J Biol Regul Homeost Agents; 2010; 24(4):403-11. PubMed ID: 21122279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management.
    Bachert C; Bousquet J; Hellings P
    Clin Transl Allergy; 2018; 8():25. PubMed ID: 29983907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines.
    Harrow B; Sedaghat AR; Caldwell-Tarr A; Dufour R
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1426-1436. PubMed ID: 27882840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.
    Klimek L; Demoly P; Price D
    Expert Rev Clin Pharmacol; 2016; 9(5):705-14. PubMed ID: 26839083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma.
    Price D; Klimek L; Gálffy G; Emmeluth M; Koltun A; Kopietz F; Nguyen DT; van Weissenbruch R; Pohl W; Kuhl HC; Scadding G; Mullol J
    Clin Mol Allergy; 2020; 18():15. PubMed ID: 32782442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis.
    Klimek L; Mullol J; Hellings P; Gevaert P; Mösges R; Fokkens W
    Expert Opin Pharmacother; 2016; 17(5):657-69. PubMed ID: 26800187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.
    De Jong HJI; Voorham J; Scadding GK; Bachert C; Canonica GW; Smith P; Wahn U; Ryan D; Castillo JA; Carter VA; Murray RB; Price DB
    World Allergy Organ J; 2020 Dec; 13(12):100490. PubMed ID: 33376573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu.
    Dollner R; Lorentz Larsen P; Dheyauldeen S; Steinsvåg S
    Allergy Rhinol (Providence); 2017 Oct; 8(3):148-156. PubMed ID: 29070272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study.
    Klimek L; Price D; Gálffy G; Emmeluth M; Koltun A; Kopietz F; Nguyen DT; van Weissenbruch R; Pohl W; Kuhl HC; Scadding G; Mullol J
    Int Arch Allergy Immunol; 2020; 181(10):754-764. PubMed ID: 32829329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis.
    van Weissenbruch R; Klimek L; Gálffy G; Emmeluth M; Koltun A; Kopietz F; Nguyen DT; Kuhl HC; Pohl W; Scadding GK; Price D; Mullol J
    J Asthma Allergy; 2020; 13():633-645. PubMed ID: 33293835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells.
    Mullol J; de Borja Callejas F; Martínez-Antón MA; Méndez-Arancibia E; Alobid I; Pujols L; Valero A; Picado C; Roca-Ferrer J
    Respir Res; 2011 Feb; 12(1):23. PubMed ID: 21352574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
    Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U
    Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.